196 related articles for article (PubMed ID: 37223611)
1. Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced
Zhou Q; Soo RA; Chang GC; Chiu CH; Hayashi H; Kim SW; Teraoka S; Goto Y; Zhou J; Ho-Fun Lee V; Kim DW; Han B; Chung Man Ho J; Lin CC; Lu S; Polli A; Calella AM; Martini JF; Wong CH; Mok T; Kim HR; Wu YL
JTO Clin Res Rep; 2023 May; 4(5):100499. PubMed ID: 37223611
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.
Solomon BJ; Bauer TM; Mok TSK; Liu G; Mazieres J; de Marinis F; Goto Y; Kim DW; Wu YL; Jassem J; López FL; Soo RA; Shaw AT; Polli A; Messina R; Iadeluca L; Toffalorio F; Felip E
Lancet Respir Med; 2023 Apr; 11(4):354-366. PubMed ID: 36535300
[TBL] [Abstract][Full Text] [Related]
3. First-Line Lorlatinib or Crizotinib in Advanced
Shaw AT; Bauer TM; de Marinis F; Felip E; Goto Y; Liu G; Mazieres J; Kim DW; Mok T; Polli A; Thurm H; Calella AM; Peltz G; Solomon BJ;
N Engl J Med; 2020 Nov; 383(21):2018-2029. PubMed ID: 33207094
[TBL] [Abstract][Full Text] [Related]
4. First-Line Lorlatinib Versus Crizotinib in
Hayashi H; Teraoka S; Goto Y; Kumagai T; Nishio M; Sugawara S; Oizumi S; Matsumura M; Okura M; Peltz G; Kato T
JTO Clin Res Rep; 2023 Apr; 4(4):100471. PubMed ID: 37007870
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Efficacy and Safety of Lorlatinib in Japanese Patients With
Teraoka S; Hayashi H; Goto Y; Nishio M; Sugawara S; Inoue T; Oizumi S; Toyoizumi S; Matsumura M; Messina R; Kato T
JTO Clin Res Rep; 2024 Mar; 5(3):100632. PubMed ID: 38434770
[TBL] [Abstract][Full Text] [Related]
6. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
[TBL] [Abstract][Full Text] [Related]
7. Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.
Seto T; Hayashi H; Satouchi M; Goto Y; Niho S; Nogami N; Hida T; Takahashi T; Sakakibara-Konishi J; Morise M; Nagasawa T; Suzuki M; Ohkura M; Fukuhara K; Thurm H; Peltz G; Nishio M
Cancer Sci; 2020 Oct; 111(10):3726-3738. PubMed ID: 32681682
[TBL] [Abstract][Full Text] [Related]
8. Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With
Solomon BJ; Bauer TM; Ignatius Ou SH; Liu G; Hayashi H; Bearz A; Penkov K; Wu YL; Arrieta O; Jassem J; Calella AM; Peltz G; Polli A; Thurm H; Mok T
J Clin Oncol; 2022 Nov; 40(31):3593-3602. PubMed ID: 35605188
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial.
Soo RA; Huat Tan E; Hayashi H; Seto T; Lin CC; Ou SI; Kim DW; Liu G; Abbattista A; Martini JF; Hooi Wong C; Toffalorio F; Solomon BJ
Lung Cancer; 2022 Jul; 169():67-76. PubMed ID: 35660971
[TBL] [Abstract][Full Text] [Related]
10. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer.
Mazieres J; Iadeluca L; Shaw AT; Solomon BJ; Bauer TM; de Marinis F; Felip E; Goto Y; Kim DW; Mok T; Reisman A; Thurm H; Polli AM; Liu G
Lung Cancer; 2022 Dec; 174():146-156. PubMed ID: 36410210
[TBL] [Abstract][Full Text] [Related]
12. Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People's Republic of China.
Lu S; Zhou Q; Liu X; Du Y; Fan Y; Cheng Y; Fang J; Lu Y; Huang C; Zhou J; Song Y; Wang K; Pan H; Yang N; Li J; Chen G; Chang J; Cui J; Liu Z; Bai C; Zhang H; Zhao H; Zhang K; Peltz G; Li H; Wu YL
J Thorac Oncol; 2022 Jun; 17(6):816-826. PubMed ID: 35307611
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.
Peng Y; Zhao Q; Liao Z; Ma Y; Ma D
Cancer; 2023 Apr; 129(8):1261-1275. PubMed ID: 36748799
[TBL] [Abstract][Full Text] [Related]
14. Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC.
Soo RA; Martini JF; van der Wekken AJ; Teraoka S; Ferrara R; Shaw AT; Shepard D; Calella AM; Polli A; Toffalorio F; Tomasini P; Chiu CH; Kowalski DM; Kim HR; Solomon BJ
J Thorac Oncol; 2023 Nov; 18(11):1568-1580. PubMed ID: 37295609
[TBL] [Abstract][Full Text] [Related]
15. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
Camidge DR; Kim HR; Ahn MJ; Yang JC; Han JY; Lee JS; Hochmair MJ; Li JY; Chang GC; Lee KH; Gridelli C; Delmonte A; Garcia Campelo R; Kim DW; Bearz A; Griesinger F; Morabito A; Felip E; Califano R; Ghosh S; Spira A; Gettinger SN; Tiseo M; Gupta N; Haney J; Kerstein D; Popat S
N Engl J Med; 2018 Nov; 379(21):2027-2039. PubMed ID: 30280657
[TBL] [Abstract][Full Text] [Related]
16. Lorlatinib Versus Crizotinib in Patients With Advanced
Solomon BJ; Liu G; Felip E; Mok TSK; Soo RA; Mazieres J; Shaw AT; de Marinis F; Goto Y; Wu YL; Kim DW; Martini JF; Messina R; Paolini J; Polli A; Thomaidou D; Toffalorio F; Bauer TM
J Clin Oncol; 2024 May; ():JCO2400581. PubMed ID: 38819031
[TBL] [Abstract][Full Text] [Related]
17. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Shaw AT; Solomon BJ; Chiari R; Riely GJ; Besse B; Soo RA; Kao S; Lin CC; Bauer TM; Clancy JS; Thurm H; Martini JF; Peltz G; Abbattista A; Li S; Ou SI
Lancet Oncol; 2019 Dec; 20(12):1691-1701. PubMed ID: 31669155
[TBL] [Abstract][Full Text] [Related]
18. Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
Horn L; Wang Z; Wu G; Poddubskaya E; Mok T; Reck M; Wakelee H; Chiappori AA; Lee DH; Breder V; Orlov S; Cicin I; Cheng Y; Liu Y; Fan Y; Whisenant JG; Zhou Y; Oertel V; Harrow K; Liang C; Mao L; Selvaggi G; Wu YL
JAMA Oncol; 2021 Nov; 7(11):1617-1625. PubMed ID: 34473194
[TBL] [Abstract][Full Text] [Related]
19. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.
Zhou C; Kim SW; Reungwetwattana T; Zhou J; Zhang Y; He J; Yang JJ; Cheng Y; Lee SH; Bu L; Xu T; Yang L; Wang C; Liu T; Morcos PN; Lu Y; Zhang L
Lancet Respir Med; 2019 May; 7(5):437-446. PubMed ID: 30981696
[TBL] [Abstract][Full Text] [Related]
20. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.
Ou SH; Ahn JS; De Petris L; Govindan R; Yang JC; Hughes B; Lena H; Moro-Sibilot D; Bearz A; Ramirez SV; Mekhail T; Spira A; Bordogna W; Balas B; Morcos PN; Monnet A; Zeaiter A; Kim DW
J Clin Oncol; 2016 Mar; 34(7):661-8. PubMed ID: 26598747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
